Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion type Assertion NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_head.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion wasGeneratedBy ECO_0000203 NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_provenance.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion wasDerivedFrom befree-2016 NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_provenance.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion SIO_000772 22547605 NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_provenance.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion evidence source_evidence_literature NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_provenance.
- NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_assertion description "[Patients with advanced NSCLC (adenocarcinoma) who were epidermal growth factor receptor tyrosine kinase inhibitor and chemotherapy naive never or light former smokers (smokers of > 100 cigarettes and ≤ 10 pack years and quit ≥ 1 year ago) were randomly assigned to continuous erlotinib or in combination with carboplatin and paclitaxel (ECP) for six cycles followed by erlotinib alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978721.RAySo66IrrO-Exs_S8zkh0HcU3_SLRPMHEWVtxjKcTalg130_provenance.